Logo image of VRCA

VERRICA PHARMACEUTICALS INC (VRCA) Stock Fundamental Analysis

NASDAQ:VRCA - US92511W1080 - Common Stock

5.35 USD
-0.25 (-4.38%)
Last: 9/2/2025, 4:03:15 PM
5.47 USD
+0.12 (+2.24%)
After Hours: 9/2/2025, 4:03:15 PM
Fundamental Rating

2

VRCA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. VRCA has a bad profitability rating. Also its financial health evaluation is rather negative. VRCA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRCA had negative earnings in the past year.
VRCA had a negative operating cash flow in the past year.
VRCA had negative earnings in each of the past 5 years.
In the past 5 years VRCA always reported negative operating cash flow.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

VRCA has a worse Return On Assets (-124.27%) than 81.03% of its industry peers.
Industry RankSector Rank
ROA -124.27%
ROE N/A
ROIC N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

With an excellent Gross Margin value of 86.46%, VRCA belongs to the best of the industry, outperforming 90.77% of the companies in the same industry.
VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRCA has more shares outstanding
VRCA has more shares outstanding than it did 5 years ago.
VRCA has a worse debt/assets ratio than last year.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

VRCA has an Altman-Z score of -13.43. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
VRCA's Altman-Z score of -13.43 is on the low side compared to the rest of the industry. VRCA is outperformed by 74.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.43
ROIC/WACCN/A
WACC13.53%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

VRCA has a Current Ratio of 1.26. This is a normal value and indicates that VRCA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of VRCA (1.26) is worse than 76.41% of its industry peers.
VRCA has a Quick Ratio of 1.17. This is a normal value and indicates that VRCA is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.17, VRCA is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.17
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

VRCA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -105.85%.
VRCA shows a small growth in Revenue. In the last year, the Revenue has grown by 5.70%.
Measured over the past years, VRCA shows a very negative growth in Revenue. The Revenue has been decreasing by -14.25% on average per year.
EPS 1Y (TTM)-105.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.41%
Revenue 1Y (TTM)5.7%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%145.35%

3.2 Future

VRCA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.85% yearly.
The Revenue is expected to grow by 100.88% on average over the next years. This is a very strong growth
EPS Next Y29.15%
EPS Next 2Y20.58%
EPS Next 3Y25.47%
EPS Next 5Y31.85%
Revenue Next Year227.39%
Revenue Next 2Y109.41%
Revenue Next 3Y89.18%
Revenue Next 5Y100.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VRCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRCA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as VRCA's earnings are expected to grow with 25.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.58%
EPS Next 3Y25.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRCA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (9/2/2025, 4:03:15 PM)

After market: 5.47 +0.12 (+2.24%)

5.35

-0.25 (-4.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-03 2025-11-03
Inst Owners32.24%
Inst Owner Change-15.37%
Ins Owners55.34%
Ins Owner Change-0.01%
Market Cap50.56M
Analysts78.18
Price Target15.3 (185.98%)
Short Float %N/A
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)51.11%
Min EPS beat(2)-0.55%
Max EPS beat(2)102.78%
EPS beat(4)2
Avg EPS beat(4)20.42%
Min EPS beat(4)-30.9%
Max EPS beat(4)102.78%
EPS beat(8)4
Avg EPS beat(8)5.32%
EPS beat(12)7
Avg EPS beat(12)17.31%
EPS beat(16)10
Avg EPS beat(16)16.92%
Revenue beat(2)2
Avg Revenue beat(2)112.72%
Min Revenue beat(2)33.57%
Max Revenue beat(2)191.87%
Revenue beat(4)2
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-137.73%
Max Revenue beat(4)191.87%
Revenue beat(8)6
Avg Revenue beat(8)80.6%
Revenue beat(12)8
Avg Revenue beat(12)59.58%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)275%
PT rev (3m)350%
EPS NQ rev (1m)-14.41%
EPS NQ rev (3m)-1025%
EPS NY rev (1m)-779.14%
EPS NY rev (3m)-801.75%
Revenue NQ rev (1m)3.71%
Revenue NQ rev (3m)-4.76%
Revenue NY rev (1m)37.36%
Revenue NY rev (3m)59.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.87
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-5.01
FCFYN/A
OCF(TTM)-5.01
OCFYN/A
SpS1.56
BVpS-1.85
TBVpS-1.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -124.27%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.46%
FCFM N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.6%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.17
Altman-Z -13.43
F-Score5
WACC13.53%
ROIC/WACCN/A
Cap/Depr(3y)37.37%
Cap/Depr(5y)830.75%
Cap/Sales(3y)3.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-105.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.41%
EPS Next Y29.15%
EPS Next 2Y20.58%
EPS Next 3Y25.47%
EPS Next 5Y31.85%
Revenue 1Y (TTM)5.7%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%145.35%
Revenue Next Year227.39%
Revenue Next 2Y109.41%
Revenue Next 3Y89.18%
Revenue Next 5Y100.88%
EBIT growth 1Y50.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-275.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-282.11%
OCF growth 3YN/A
OCF growth 5YN/A